UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.DC  20549

FORM 10-Q


Form 10-Q/A
(Amendment No. 1)

(Mark One)

one)

xQuarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2015
oTransition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from ______________ to _____________

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2015

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number:333-173873

000-54770

MCPI, Inc.

 (Exact

(Exact name of registrant as specified in its charter)

Nevada45-0704149

(State or other jurisdiction of

incorporation or organization)

incorporation)

(I.R.S.IRS Employer

Identification ID Number)

454 SW Coast Highway, Newport, OR 97365

(Address of principal executive offices)

  Tel:

(214) 666-8364

 (Registrant’s

(Issuer’s telephone number, including area code)

Former address: 817 NW Hill Street Bend, OR 97701

 (Former name, former address and former fiscal year, if changed since last report)

Indicate by check marknumber)


Check whether the registrantissuer (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the precedingpast 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 Yes  YES  x  NO  Noo

¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website,Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of RegulationsRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes YES  x  NO   Noo

¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,”filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large Accelerated Fileraccelerated filer o
Accelerated Filerfiler o
Non-Accelerated FilerNon-accelerated filer o  Do not check if a smaller
Smaller reporting company)
company Smaller Reporting Company  x


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

: YES  Yes Noo  NO  x

The

State the number of shares outstanding of each of the Registrant'sissuer's classes of common equity as of the latest practicable date: August 1, 2016: 50,220,000 shares of common stock, $0.0001 par value as$0.001


MCPI, Inc.

Form 10-Q/A for the Quarter ended September 30, 2015

Table of November 16, 2015, was 50,220,000.

Contents
 1Page
Part I - Financial Information 

TABLE OF CONTENTS

ItemPage
  
PART I – FINANCIAL INFORMATIONItem 1 - Financial Statements43
 Item 1Financial Statements4
Item 2Management’s - Management's Discussion and Analysis of Financial Condition and Results of Operations1715
 
Item 3 - Quantitative and Qualitative Disclosures About Market Risk24
Item 4Controls and Procedures2417
  
PART II – OTHER INFORMATIONItem 4 - Controls and Procedures2617
 Item 1
Legal ProceedingsPart II - Other Information 26
 
Item 1A1 - Legal ProceedingsRisk Factors2618
 
Item 1A - Risk Factors18
Item 2Unregistered - Sales of Unregistered Equity Securities and Use of Proceeds2618
 
Item 3 - Defaults Upon Senior Securities2618
 
Item 4 - Mine Safety Disclosures2618
 
Item 5 - Other Information2618
 
Item 6 - ExhibitsExhibits18
 27
Signatures28

218

 

Forward-Looking

2


Part I - Financial Information

Item 1 - Financial Statements

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements of the Registrant to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Registrant’s plans and objectives are based, in part, on assumptions involving it continuing as a going concern and executing on its stated business plan and objectives. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Registrant. Although the Registrant believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Registrant or any other person that the objectives and plans of the Registrant will be achieved.

As used in this Quarterly Report, the terms "we", "us", "our", "Med-Cannabis Pharma", “Registrant”, and “Issuer” refers to


MCPI, Inc. unless the context clearly requires otherwise.

3
Balance Sheets

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

 MCPI, Inc.

CONSOLIDATED BALANCE SHEETS

As of

September 30, 2015 and

December 31, 2014

ASSETS  
         
   9/30/2015   12/31/2014 
   (unaudited)   (audited) 
Current assets:        
Cash and equivalents $31,082  $14,763 
Accounts receivable  10,000   —   
  Other receivables  83,300   —   
Total current assets  124,882   14,763 
         
  Fixed assets (net)  53,663   —   
  Other assets  —     —   
         
Total assets: $178,544  $14,763 
         
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
         
Current liabilities:        
Accounts payable $44,490  $6,285  
Accounts payable – related party  —     —   
Accrued expenses  45,888   26,333  
Accrued expenses – related party  41,628   —   
Deferred revenue  —     5,000  
Notes payable to stockholders  873,597   323,579  
   1,005,604   361,197  
         
Total liabilities $1,005,604  $361,197  
         
Stockholders’ (deficit):        
Preferred stock, $0.0001 par value, 25,000,000 shares authorized;
no shares issued and outstanding
  —     —   
Common stock, $0.0001 par value, 500,000,000 shares authorized;
50,220,000 and 50,170,000 shares issued and outstanding, respectively
  5,022   5,017  
Additional paid-in capital  59,381,818   59,066,823  
Accumulated Deficit  (60,213,900)  (59,418,274) 
         
Total stockholders’ (deficit) $(827,060) $(346,424) 
         
Total liabilities and stockholders’ (deficit) $178,544  $14,763  
         



  (RESTATED)    
  (Unaudited)  (Audited) 
  September 30,  December 31, 
  2015  2014 
ASSETS      
       
Current Assets      
Cash and cash equivalents $8,376  $14,763 
         
    Total Current Assets
  8,376   14,763 
         
Property, Plant and Equipment - at cost  58,354    
Less: Accumulated depreciation  (6,974)   
         
    Net Property and Equipment
  51,380    
         
    Total Assets
 $59,756  $14,763 
         
         
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)        
         
Current Liabilities        
Accounts payable        
Third parties $4,884  $6,285 
Accrued expenses        
Third parties  37,221   26,333 
Related parties  35,947    
Accrued interest payable        
Related parties  31,628    
Deferred revenue     5,000 
Note payable to stockholder  538,504   323,579 
         
    Total Liabilities
  648,184   361,197 
         
Commitments and Contingencies        
         
Stockholders' Equity (Deficit)        
Preferred stock - $0.001 par value        
25,000,000 shares authorized.        
None issued and outstanding.      
Common stock - $0.001 par value.        
500,000,000 shares authorized.        
50,220,000 and 50,170,000 shares        
issued and outstanding  50,220   50,170 
Additional paid-in capital  59,336,620   59,021,670 
Accumulated deficit  (59,975,268)  (59,418,274)
         
Total Stockholders' Equity (Deficit)  (588,428)  (346,434)
         
Total Liabilities and Stockholders’ Equity (Deficit) $59,756  $14,763 




The financial information presented herein has been prepared by management
without audit by independent certified public accountants.
The accompanying notes to the financial statements are an integral part of these  financial statements.


4
 

3


MCPI, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

For The

Statements of Operations and Comprehensive Loss
Nine and Three and Nine Months Endedmonths ended September 30, 2015 and 2014

(unaudited)

  For the three months ended
September 30,
 For the nine months ended
September 30,
  2015 2014 2015 2014
Revenues, net  59,555  $—    $69,555  $—   
                 
Cost of revenues  77,419   —     86,650   —   
                 
Gross profit  (17,864)  —     (17,095)  —   
                 
Expenses:                
Depreciation and amortization  (29)  —     7,682     
General and administrative  146,893   34,022   337,721   77,662 
Consulting fees  16,927   8,050   345,420   10,169 
Legal Fees  3,646   6,363   12,259   18,941 
Accounting fees  11,754   —     22,539   4,000 
Transfer agent fees  1,320   6,451   2,251   2,103 
   Total Expenses  180,510   48,435   727,870   112,875 
                 
(Loss) from operations  (198,374)  (48,435)  (744,965)  (112,875)
                 
Other income (expense)                
Interest expense  (27,509)  (3,753)  (50,661)  (7,862)
Total other income (expense)  (27,509)  (3,753)  (50,661)  (7,862)
                 
Provision for income taxes  —     —     —     —   
                 
Net (loss)  (225,883) $(52,188) $(795,626) $(120,737)
                 

(Loss) per common share,

basic and diluted

  **   **   (0.02)  ** 
                 

Weighted average number of common shares outstanding,

basic and diluted

  50,220,000   210,000,000   50,213,094   208,804,348 
                 
** Less than $0.01                


(Unaudited)


  (RESTATED)     (RESTATED)    
  Nine months  Nine months  Three months  Three months 
  ended  ended  ended  ended 
  September 30,  September 30,  September 30,  September 30, 
  2015  2014  2015  2014 
             
Revenues $20,652  $  $10,652  $ 
Cost of Sales  (25,467)     (16,236)   
                 
    Gross Profit
  (4,815)     (5,584)   
                 
Operating expenses                
Professional fees  396,114   35,213   47,292   20,864 
General and administrative costs  125,939   77,662   (64,888)  34,022 
Depreciation and amortization  6,974      (737)   
                 
    Total operating expenses
  529,027   112,875   (18,333)  48,435 
                 
Loss from operations  (533,842)  (112,875)  (12,749)  (48,435)
                 
Other income (expense)                
Interest expense on notes payable to stockholders  (23,152)  (7,862)     (3,753)
                 
Loss before provision for income taxes  (556,994)  (120,737)  (12,749)  (52,188)
                 
Provision for income taxes            
                 
Net loss  (556,994)  (120,737)  (12,749)  (52,188)
                 
Other comprehensive income            
                 
Comprehensive loss $(556,994) $(120,737) $(12,749) $(52,188)
                 
Loss per weighted-average share of common stock outstanding,                
computed on net loss - basic and fully diluted $(0.01) $(0.00) $(0.00) $(0.00)
                 
Weighted-average number of shares of common stock outstanding -                
basic and fully diluted  50,213,094   208,804,348   50,220,000   210,000,000 




The financial information presented herein has been prepared by management
without audit by independent certified public accountants.
The accompanying notes to the financial statements are an integral part of these  financial statements.


5
 

4


MCPI, Inc.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ (DEFICIT)

For The

Statement of Changes in Stockholders’ Equity (Deficit)
Nine Month Period Endedmonths ended September 30, 2015 and

The Year Endedended December 31, 2014


(Unaudited)

   Common Stock   Paid-in   Accumulated     
   Shares   Amount   Capital   Deficit   Totals 

Balance,

December 31, 2013

  210,000,000  $21,000  $59,014,061  $(59,105,772) $(70,711)
                     
Cancellation of shares of
common stock
  (159,930,000)  (15,993)  15,993   —     —   
                     
Forgiveness of debt  —     —     1,806   —     1,806 
                     
Issuance of shares of
common stock to consultant
  100,000   10   29,990   —     30,000 
                     
Imputed interest on related party loan  —     —     4,973   —     4,973 
                     
Net (loss) for the period  —     —     —     (312,502)  (312,502)
                     

Balance,

December 31, 2014 

  50,170,000  $5,017  $59,066,823  $(59,418,274) $(346,434)
                     
Issuance of shares of common stock
for services
  50,000   5   14,995   —     15,000 
                     
Donated Capital  —     —     300,000   —     300,000 
                     
Net (loss) for the period  —     —     —     (795,626)  (795,626)
                     
Balance, September 30, 2015 (unaudited)  50,220,000   5,022   59,381,818   (60,213,900)  (827,060)



        Additional       
  Common Stock  paid-in  Accumulated    
  Shares  Amount  capital  Deficit  Total 
                
Balances at January 1, 2014  210,000,000  $21,000  $59,014,061  $(59,105,772) $(70,711)
                     
Effect of change in par value on March 23, 2016     189,000   (189,000)      
                     
Cancellation of common stock  (159,930,000)  (159,930)  159,930       
                     
Forgiveness of debt        1,806      1,806 
                     
Issuance of common stock for consulting fees  100,000   100   29,900      30,000 
                     
Imputed interest on related party loan        4,973      4,973 
                     
Net loss for the year           (312,502)  (312,502)
                     
Balances at December 31, 2014  50,170,000   50,170   59,021,670   (59,418,274)  (346,434)
                     
Issuance of common stock for consulting fees  50,000   50   14,950      15,000 
                     
Contributed capital        300,000      300,000 
                     
Net loss for the period (RESTATED)           (556,994)  (556,994)
                     
Balances at September 30, 2015  50,220,000  $50,220  $59,336,620  $(59,975,268) $(558,428)




The financial information presented herein has been prepared by management
without audit by independent certified public accountants.
The accompanying notes to the financial statements are an integral part of these  financial statements.


6
 

5


MCPI, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For The

Statements of Cash Flows
Nine months Endedended September 30, 2015 and 2014

(unaudited)

  For the nine months ended
September 30,
  2015 2014
Cash flows from operating activities:        
Net (loss) $(795,626) $(120,737)
Adjustments to reconcile net (loss) to net cash provided (used) by operating activities        
Depreciation expense  7,682   —   
Shares issued for services  15,000   —   
Donated capital  300,000   —   
Imputed interest on related party loan  —     4,973 
Changes in operating assets and liabilities:        
Change in accounts receivable  (93,800)  —   
Change in other assets  —     (3,000)
Change in accounts payable  38,207   (17,752)
Change in accrued expenses  61,183   —   
Change in deferred revenue  (5,000)  —   
         
Net cash provided (used) by operating activities  (472,354)  (136,516)
         
Cash flows from investing activities:        
  Purchased of fixed assets  (61,345)  —   
  Net cash (used in) investing activities  (61,345)  —   
         
Cash flows from financing activities:        
Increase in notes payable to a stockholder  550,018   140,180 
         
Net cash (used in) financing activities  550,018   140,180 
         
Net increase (decrease) in cash  16,319   3,664 
         
Cash – beginning of period  14,763   37 
         
Cash – end of period $31,082  $3,701 
         
Non-cash investing and financing activities:        
Cash Paid During Year for Interest Expense  0   0 
 Shares Issued for Services  15,000   26,000 
 Cancellation of Common   Shares  0   (30,000)


(Unaudited)


  (RESTATED)    
  Nine months  Nine months 
  ended  ended 
  September 30,  September 30, 
  2015  2014 
Cash Flows from Operating Activities      
Net income (loss) for the period $(556,994) $(120,737)
Adjustments to reconcile net loss to net cash used in operating activities        
Depreciation and amortization  6,974    
Common stock issued for professional fees  15,000    
Imputed interest on related party loan     4,973 
(Increase) Decrease in        
Other assets     (3,000)
Increase (Decrease) in        
Accounts payable - third party  (1,400)  (17,752)
Accounts payable - related parties  35,947    
Accrued expenses - third party  10,888    
Accrued expenses - related parties  31,628    
Deferred revenues  (5,000)   
         
Net cash used in operating activities  (462,957)  (136,516)
         
Cash Flows from Investing Activities        
Expenses paid on behalf of related party      
Acquisition of property and equipment  (58,354)   
         
Net cash used in investing activities  (393,449)   
         
Cash Flows from Financing Activities        
Contributed capital  300,000    
Cash received from notes payable to stockholders  214,925   140,180 
         
Net cash provided by financing activities  514,925   140,180 
         
Increase (Decrease) in Cash  (6,387)  3,664 
         
Cash at beginning of period  14,763   37 
         
Cash at end of period $8,376  $3,701 
         
         
Supplemental Disclosure of Interest and Income Taxes Paid        
Interest paid during the period $  $ 
Income taxes paid during the period $  $ 
         
Supplemental Disclosure of Non-Cash Investing and        
Financing Activities $  $ 




The financial information presented herein has been prepared by management
without audit by independent certified public accountants.
The accompanying notes to the financial statements are an integral part of these  financial statements.


7
 

6


MCPI, Inc.

September 30, 2015

(unaudited)

NOTE 1 – Summary of Significant Accounting Policies

Unaudited Interim

Notes to Financial Information

The accompanying Consolidated Balance Sheet as of Statements

September 30, 2015 and December 31, 2014 Consolidated Statements
(Unaudited)


Note A - Background and Description of Operations for the three and nine months ended September 30, 2015, Consolidated Statement of Stockholder’s (Deficit) and the Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles accepted in the United States of America (“GAAP”). In the opinion of the company’s management, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and included all adjustments necessary for the fair presentation of the Company’s statement of financial position at September 30, 2015 and its results of operations and its cash flows for the period ended September 30, 2015. The results for the period ended September 30, 2015 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015.

Organization

Business


MCPI, Inc. (“CompanyCompany” or Med-Cannabis Pharma“Med-Cannabis Pharma”) was incorporated under the laws of the State of Nevada on February 23, 2011.  The Company was originally incorporated as Southwest China Imports, Inc. on February 23, 2011 in the State of Nevada.  The Company’s initial business plan was to import high-end handmade lace wigs, hairpieces, and other beauty supplies and accessories manufactured overseas into the United States.  In June 2014, the Company changed its name to Med-Cannabis Pharma, has threeInc. and implemented a new business plan to enter into the retail sale of medical and personal use  marijuana, where allowable.  In October 2015, the Company changed its name to MCPI, Inc.

Effective March 31, 2016, the Company ceased activities in all of its subsidiaries two which are wholly owned:and disposed of Med-Pharma Management, Inc. and High Desert MMJ, Inc.  Prior thereto, the Company’s  subsidiaries were Medical Management Systems, Inc., an Oregon corporation engaged in providing back-office and support services to marijuana dispensaries in the State of Oregon; Med-Pharma Management, Inc., a Washington State corporation which has operations aswas formed to own, manage or provide back-office and support services to marijuana dispensaries in Washington State; and High Desert MMJ, Inc. an Oregon corporation, which is a 99.0% partner in Emerald Mountain Organics, an Oregon joint venture, formed to facilitate the development and growing of medical marijuana plants for wholesale distribution to licenced dispensaries in the State of Oregon.

As of September 30, 2015, Medical Management Systems, Inc. held a Management Contract for three marijuana dispensaries located in Newport, Bend and has begun to record revenueCottage Grove, Oregon; which are owned by a company controlled by a related party.  This Management Contract was terminated by the consent of both parties, effective March 31, 2016.   Med-Pharma only conducted introductory due diligence efforts in the State of Washington and, Med-Pharma Management, Inc. which has no operationscurrently, had abandoned all activities in the State of Washington.  Emerald Mountain Organics had, as of September 30, 201530,2015, established an early-phase growing operation and has not recognized an revenue. Thegenerated nominal sales.

During the first 10 days of October 2015, the Company’s other subsidiary, is aHigh Desert MMJ, Inc., learned that the 1.0% minority partner in the Emerald Mountain Organics joint venture had absconded with all of the assets of the joint venture.  Efforts to locate and recover either the individuals representing said 1.0% minority partner or the said absconded assets were unsuccessful.  Accordingly, effective October 10, 2015, High Desert MMJ, Inc. whereabandoned the Emerald Mountain Organics joint venture and wrote off said investment.  The cumulative start-up losses in the Company’s consolidated financial statements for the Emerald Mountain Organics joint venture, through the date of abandonment were approximately $53,000 and the Company owns 99%. High Desert MMJ did not have any salesrecognized a loss on the stolen assets of approximately $51,000 during the quarter ended December 31, 2015.

On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.  The Settlement Agreement relates to the Company’s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.  The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of September 30, 2015 but did incur set-up coststhe date of the Settlement Agreement.

The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the Company’s ‘grow’ operation.,

Basis of Presentation

The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (US GAAP) for financial information and in accordance with the Securities and Exchange Commission’s (SEC) Regulation S-X. They reflect all adjustments which are, in the opinionservices of the Company’s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.  Bendor disputed this claim.  To resolve the dispute, the parties agreed to forgive the accrued management necessary forfees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.  Additionally, the Company agreed to assign a fair presentationtrademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.  The effect of the financial position and operating results asJune 1, 2016 Settlement Agreement , due to the timing of and for the period ended September 30, 2015.

Usethis release of Estimates

The accompanyingthese amended financial statements and this transaction, is reflected in the accompanying consolidated financial statements.


Note B - Preparation of Financial Statements

The Company follows the Company have been preparedaccrual basis of accounting in accordance with generally accepted accounting principles and has elected a year-end of December 31.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America. Because a precise determinationAmerica requires management to make estimates and assumptions that affect the reported amounts of many assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

7


MCPI, Inc.
Notes to Financial Statements
September 30, 2015 and December 31, 2014
(Unaudited)


Note B - Preparation of Financial Statements - Continued

Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud.  The Company’s system of internal accounting control is designed to assure, among other items, that 1) recorded transactions are valid; 2) valid transactions are recorded; and 3) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

For segment reporting purposes, the Company operated in only one industry segment during the periods represented in the accompanying financial statements and makes all operating decisions and allocates resources based on the best benefit to the Company as a whole.

During interim periods, the Company follows the accounting policies set forth in its annual audited financial statements filed with the U. S. Securities and Exchange Commission on its Annual Report on Form 10-K for the year ended December 31, 2014.  The information presented within these interim financial statements may not include all disclosures required by accounting principles generally accepted in the United States of America and the users of financial information provided for interim periods should refer to the annual financial information and footnotes when reviewing the interim financial results presented herein.

In the opinion of management, the accompanying interim financial statements, prepared in accordance with the U. S.  Securities and Exchange Commission’s instructions for Form 10-Q, are unaudited and contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations and cash flows of the Company for the respective interim periods presented.  The current period results of operations are not necessarily indicative of results which ultimately will be reported for the full fiscal year ending December 31, 2015.

The accompanying consolidated financial statements contain the accounts of MCPI, Inc. ; its wholly-owned subsidiaries, Medical Management Systems, Inc., Med-Pharma Management, Inc., High Desert MMJ, Inc.; and it’s majority-owned joint venture, Emerald Mountain Organics.  All significant intercompany transactions have been eliminated.  The consolidated entities are collectively referred to as “Company”.

Note C - Correction of an Error and Restatement of Financial Statements

During the third and fourth quarter of 2015, former management, independently, undertook procedures, protocols and decisions to circumvent the reporting nature and requirements of the Management Agreement that Medical Management Systems, Inc, a wholly-owned subsidiary of the Company, had with medical marijuana dispensaries owned by an entity controlled by personnel in common with the Company’s controlling shareholder.  It is believed that these individuals also conspired with the minority joint venture partners in Emerald Mountain Organics to facilitate the theft of all operating assets and operations of the joint venture.  Current management, with the assistance of outside consultants and input from the Company’s controlling shareholder and owner of the medical marijuana dispensaries covered by the Medical Management Systems Management Contract, identified the errors and mistatements applied by former management and has made the appropriate corrections in the accompanying financial statements.  Additionally, the Company has initiated litigation against the Company’s former President and Chief Executive Officer and others to recover either the absconded assets or their value, the value of the products in the then-current growing cycle and other damages incurred by the Company as a result of the alleged misappropriations.  It is the opinion of current management and the Company’s controlling shareholder that all appropriate corrective actions have been taken and applied.  The accompanying financial statements reflect the proper accounting for the Management Agreement.

On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.  The Settlement Agreement relates to the Company’s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.  The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.

The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company’s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.  Bendor disputed this claim.  To resolve the dispute, the parties agreed to forgive the accrued management fees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.  Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.  The effect of the June 1, 2016 Settlement Agreement , due to the timing of this release of these amended financial statements and this transaction, is reflected in the accompanying consolidated financial statements.

8


MCPI, Inc.
Notes to Financial Statements
September 30, 2015 and December 31, 2014
(Unaudited)


Note C - Correction of an Error and Restatement of Financial Statements - Continued

The effect of the aforementioned error in the first paragraph above caused an overstatement of total assets of approximately $25,000, an overstatement of total liabilities of approximately $22,000, an overstatement of reported revenues of approximately $49,000, an overstatement of cost of sales of approximately 61,000 and operating expenses of approximately $198,000 for the nine months ended September 30, 2015.  Other differences were primarily caused by the June 1 Settlement Agreement.

The effect of any and all changes discussed above are reflected in the accompanying restated financial statements as of the respective effective date of the related transaction and the effect of the corrections are summarized below by fiscal period and cumulatively.

  as originally  effect of    
  reported  adjustments  as restated 
Balance Sheet         
Cash and cash equivalents $31,082  $(22,706) $8,376 
Accounts receivable  93,300   (93,300)   
Property and equipment, net  53,663   (2,283)  51,380 
    Total assets
 $178,544  $(118,788) $59,756 
             
Accounts payable $44,490  $(39,606) $4,884 
Accrued expenses  87,516   17,280   104,796 
Notes payable to stockholder  873,597   (335,093)  538,504 
    Total liabilities
  1,005,604   (357,420)  648,184 
Stockholders’ deficit  (827,060)  238,632   (588,428)
    Total liabilities and stockholders’ deficit
 $178,544  $(118,788) $59,756 
             
Statement of Operations - Nine months ended September 30, 2015            
Revenues $69,555  $(48,903) $20,652 
Cost of Sales  (86,650)  61,183   (25,467)
Gross profit  (17,095)  12,280   (4,815)
Professional fees  382,497   (13,617)  396,114 
General and administrative expenses  337,721   (211,782)  125,939 
Depreciation and amortization  7,682   (708)  6,974 
Interest expense  50,661   (27,509)  23,152 
    Net Loss
 $(795,626) $(238,632) $(556,994)
    Earnings per share
 $(0.02) $0.01  $(0.01)
             
Statement of Operations - Three months ended September 30, 2015            
Revenues $59,555  $(48,903) $10,652 
Cost of Sales  (77,419)  61,183   (16,236)
Gross profit  (17,864)  12,280   (5,584)
Professional fees  33,646   13,646   47,292 
General and administrative expenses  146,893   (211,781)  (64,888)
Depreciation and amortization  (29)  708   (737)
Interest expense  27,509   (27,509)   
    Net Loss
 $(225,883) $127,493  $(12,749)
    Earnings per share
 $(0.00) $(0.00) $(0.00)

Note D - Going Concern Uncertainty

The Company is in the initial phases of providing back-office and support services to marijuana dispensaries and participates in a marijuana development and growing operation, all located in the State of Oregon.  As the dispensaries and growing operations were in the initial start-up phases, neither operation was profitable as of September 30, 2015.  Further, the Company’s overall efforts have been limited to organizational activities.  There is no assurance that the Company will be able to successful in the implementation of this business plan.

The Company has no operating history, limited cash on hand, no operating assets and has a business plan with inherent risk.  Because of these factors, the Company’s auditors have issued an audit opinion on the Company’s financial statements which includes a statement describing our going concern status.  This means, in the auditor’s opinion, substantial doubt about our ability to continue as a going concern exists at the date of their opinion.

9


MCPI, Inc.
Notes to Financial Statements
September 30, 2015 and December 31, 2014
(Unaudited)


Note D - Going Concern Uncertainty - Continued

The Company’s current management anticipates that the initial capitalization will be sufficient to maintain the corporate status of the Company for the immediate future.  Because of the Company's lack of operating assets, the Company’s continuance may become fully dependent upon either future sales of securities and/or advances or loans from significant stockholders or corporate officers to provide sufficient working capital to preserve the integrity of the corporate entity during the development phase.

The Company's continued existence is dependent upon its ability to implement its business plan, generate sufficient cash flows from operations to support its daily operations, and provide sufficient resources to retire existing liabilities and obligations on a timely basis.  The Company faces considerable risk in it’s business plan and a potential shortfall of funding due to our uncertainty to raise adequate capital in the equity securities market.

The Company is dependent upon existing cash balances to support its day-to-day operations.  In the event that working capital sufficient to maintain the corporate entity and implement our business plan is not available, the Company’s existing controlling stockholders intend to maintain the corporate status of the Company and provide all necessary working capital support on the Company's behalf.  However, no formal commitments or arrangements to advance or loan funds to the Company or repay any such advances or loans exist.  There is no legal obligation for either management or existing controlling stockholders to provide additional future events,funding. Further, the preparationCompany is at the mercy of financial statementsfuture economic trends and business operations for the Company’s existing controlling stockholders to have the resources available to support the Company.

The Company anticipates offering future sales of equity securities.  However, there is no assurance that the Company will be able to obtain additional funding through the sales of additional equity securities or, that such funding, if available, will be obtained on terms favorable to or affordable by the Company.

The Company’s Articles of Incorporation authorizes the issuance of up to 25,000,000 million shares of preferred stock and 500,000,000 shares of common stock.  The Company’s ability to issue preferred stock may limit the Company’s ability to obtain debt or equity financing as well as impede the implementation of the Company’s business plan.  The Company’s ability to issue these authorized but unissued securities may also negatively impact our ability to raise additional capital through the sale of our debt or equity securities.

In such a period necessarily involvesrestricted cash flow scenario, the useCompany would be unable to complete its business plan steps, and would, instead, delay all cash intensive activities.  Without necessary cash flow, the Company may become dormant during the next twelve months, or until such time as necessary funds could be raised in the equity securities market.

While the Company is of the opinion that good faith estimates whichof the Company’s ability to secure additional capital in the future to reach its goals have been made, using careful judgment. Actual results may vary from these estimates.

Cash and Cash Equivalents

For purposes of the statement of cash flows,there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.

Note E - Summary of Significant Accounting Policies

1.Cash and cash equivalents

The Company considers highly liquid financial instruments purchasedall cash on hand and in banks, certificates of deposit and other highly-liquid investments with a maturitymaturities of three months or less, when purchased, to be cash and cash equivalents. As

2.Organization costs

The Company has adopted the provisions of provisions required by the Start-Up Activities topic of the FASB Accounting Standards Codification whereby all costs incurred with the incorporation and reorganization, post-bankruptcy, of the Company were charged to operations as incurred.

3.Revenue recognition

Revenue is recognized by the Company at the point at which a transaction is delivered or services are provided to a consumer at a fixed price, collection is reasonably assured, the Company has no remaining performance obligations and no right of return by the purchaser exists.

10


MCPI, Inc.
Notes to Financial Statements
September 30, 2015 the Company had $ 31,082 in cash and equivalents and $14,763 at December 31, 2014.

2014
(Unaudited)


Note E - Summary of Significant Accounting Policies - continued

4.8Income taxes

Investments

The Company accounts for its marketable securities, which are classified as trading securities, in accordance with generally accepted accounting principles for certain investments in debt and equity securities, which requires that trading securities be carried at fair value. Unrealized gains and losses due to changes in fair value as well as realized gains and losses resulting from sales of securities are reported as Other Income/Expensesfiles income tax returns in the statementUnited States of operations. Fair valueAmerica and various states, as appropriate and applicable.  The Company is no longer subject to U.S. federal, state and local, as applicable, income tax examinations by regulatory taxing authorities for any period prior to January 1, 2011.

The Company uses the asset and liability method of the securities is based upon quoted market prices in active markets or estimated fair value when quoted market prices are not available. The cost basisaccounting for realized gains and losses is determined on a specific identification basis. As ofincome taxes.  At September 30, 2015 and December 31, 2014, respectively, the deferred tax asset and deferred tax liability accounts, as recorded when material to the financial statements, are entirely the result of temporary differences.  Temporary differences generally represent differences in the recognition of assets and liabilities for tax and financial reporting purposes, primarily accumulated depreciation and amortization, allowance for doubtful accounts and vacation accruals.

The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification.  The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority.  As a result of the implementation of Codification’s Income Tax Topic, the Company had no investments.

Fair Value of Financial Instruments

ASC 820, “Fair Value Measurements” and ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

LevelDescription
Level 1Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The estimated fair values of the Company’s financial instruments are as follows:

 Fair Value Measurement at September 30, 2015 Using:
         

 

 

 

 

 

Description

 

 

 

 

 

 

9/30/15

 

Quoted

Prices In

Active

Markets For

Identical

Assets 

(Level 1)

 

 

Significant

Other

Observable

Inputs 

(Level 2)

 

 

 

Significant

Unobservable

Inputs 

(Level 3)

Assets        
 Cash and equivalents$31,082$31,082$-$-
 $31,082$31,082$-$-
         
Liabilities        
 Accounts payable$44,490$44,490$-$-
 Accrued expenses 87,516 87,516 - -
 Note payable to stockholder873,597873,597 - -

did not incur any liability for unrecognized tax benefits.

5.9Income (Loss) per share

 

 

 

Fair Value Measurement at December 31, 2014 Using:

         

 

 

 

 

 

Description

 

 

 

 

 

 

12/31/14

 

Quoted

Prices In

Active

Markets For

Identical

Assets 

(Level 1)

 

 

Significant

Other

Observable

Inputs

(Level 2)

 

 

 

Significant

Unobservable

Inputs 

(Level 3)

Assets        
 Cash and equivalents$14,763$14,763$-$-
 $14,763$14,763$-$-
         
Liabilities        
 Accounts payable$6,285$6,285$-$-
 Accrued Expenses 26,333 26,333    
 Deferred Revenue 5,000 5,000 - -
 Note payable to stockholder$323,579$323,579$-$-

Revenue Recognition

For the quarter and nine months ended September 30, 2015, the Company realized $59,555 and 69,555, respectively, in revenue and $0 in 2014.

The Company recognizes revenue in accordance with ASC 605-10, "Revenue Recognition in Financial Statements". Revenue will be recognized only when all of the following criteria have been met:

Persuasive evidence of an arrangement exists; · Ownership and all risks of loss have been transferred to buyer, which is generally upon shipment; · The price is fixed and determinable; and · Collectability is reasonably assured.

Revenue is recorded net of any sales taxes charged to customers.

Net Loss per Share Calculation

Basic net lossearnings (loss) per common share is computed by dividing the net loss attributableincome (loss) available to common stockholders by the weighted-average number of common shares outstanding forduring the period. Dilutedrespective period presented in our accompanying financial statements.

Fully diluted earnings (loss) per sharesshare is computed similar to basic lossincome (loss) per share except that the denominator is increased to include the number of additional common shares that would have beenstock equivalents (primarily outstanding options and warrants).

Common stock equivalents represent the dilutive effect of the assumed exercise of the outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the potential common shares had been issued and if the additional common shares were dilutive. During the periods ended September 30, 2015 and December 31, 2014 and since inception the Company had nostock equivalents are considered dilutive financial instruments issued or outstanding.

10

Income Taxes

The Company accounts for income taxes pursuant to FASB ASC 740, Income Taxes. Under FASB ASC 740-10-25, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

The Company maintains a valuation allowance with respect to deferred tax assets. Med-Cannabis Pharma establishes a valuation allowance based upon the potential likelihood of realizingCompany’s net income (loss) position at the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment about its ability to realize the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

Fiscal Year

The Company elected December 31st for its fiscal year end.

NOTE 2 – Going Concern

The Company plans to acquire medical marijuana collectives and/or medical marijuana dispensaries, which are currently in operations legally within the states that medical marijuana has been approved and is legal. Currently the Company has existing dispensaries in the state of Oregon. In addition, the Company intends to further expand by opening new medical marijuana collectives and medical marijuana dispensaries in locations where an acquisition is not readily available such as states where medical marijuana has been newly legalized.

While management of the Company believes that Med-Cannabis Pharma will be successful in its planned operating activities under its business plan and capital formation activities, there can be no assurance that it will be able to successfully execute on either of these or that it will be able to generate adequate revenues to earn a profit or sustain its operations.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United State of America, which contemplate continuation of the Company as a going concern. The Company has not established a source of revenues sufficient to cover its operating costs, and as such, has incurred an operating loss since its inception. Further, as of September 30, 2015, the Company had a working capital deficiency of ($880,722). These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern.

11
calculation date.

NOTE 3 – Fixed Assets

   09/30/15   12/31/14 
Grow lights $52,845  $—   
Construction-in-process  8,500   —   
Gross Fixed Assets  61,345   —   
Accumulated depreciation  (7,682)  —   
Net Fixed Assets $53,662  $—   

The Company purchased $61,345 of fixed assets during the nine months ended September 30, 2015. Depreciation expense for the three months ended September 30, 2015 was a credit of $29 due to a correction and was $7,682 for the nine months ended September 30, 2015.

NOTE 4 – Common Stock

The total number of common shares authorized that may be issued by the Company is 500,000,000 shares with a par value of $0.0001 per share.

On January 15, 2015the Company issued an aggregate of 50,000 shares during the period ending September 30, 2015 for consulting services rendered in conjunction with the evaluation of a new location. The stock was valued at $0.30/share, the closing price on January 15, 2015, the date of the agreement.

On July 28, 2014, Big Sky Oil, Inc., the majority shareholder of Med-Cannabis Pharma Inc. (the “Company”), returned to the Company’s treasury 159,930,000 shares of the Company’s common stock it had purchased from prior management. Big Sky agreed to return these shares to the treasury for use in future possible issuances by the Company.

During the period ended March 31, 2015 South Beach Live, Inc. transferred 1,000,000 shares of its stock in MCPI to consultants for ongoing services associated with marketing strategies. South Beach Live, Inc. is a related party and does not expect to be repaid for this transaction which was treated as an expense and donated capital by MCPI.

During the period ending December 31, 2014 the Company issued an aggregate of 100,000 shares for consulting services rendered in conjunction with store management and they were valued at $30,000 using the closing price on the date the shares were granted.

As of September 30, 2015 and 2014, respectively, the Company had 50,220,000 shares of its common stock issued and outstanding.

NOTE 5 – Preferred Stock

The total number of preferred shares authorized that maydoes not have any outstanding items which could be issued by the Company is 25,000,000 shares with a par value of $0.0001 per share.

As of September 30, 2015, the Company had no shares of its preferred stock issued and outstanding.

deemed to be dilutive.

6.12New and Pending Accounting Pronouncements

NOTE 6 – Income Taxes

The provision (benefit) for income taxes for the period from February 23, 2011 (inception) September 30, 2015 was as follows, assuming a 35 percent effective tax rate:

  September 30, 2015 For the year
ended
12/31/14
Current tax provision:        
            Federal        
                        Taxable income $—    $—   
                        Total current tax provision $—    $—   
Deferred tax provision:        
         Federal        
                    Loss carryforwards $425,114  $134,432 
Change in valuation allowance  (425,114)  (134,432)
                    Total deferred tax provision $—    $—   

As of September 30, 2015, the Company had approximately $1,265,733 in tax loss carryforwards that can be utilized in future periods to reduce taxable income through 2032.

The Company provided a valuation allowance equal to the deferred income tax assets through September 30, 2015 because it is not presently known whether future taxable income will be sufficient to utilize the tax loss carryforwards.

The Company has no uncertain tax positions.

NOTE 7 – Change of Control

On March 27, 2014 the shareholders of MCPI, Inc. sold their shares, 210,000,000, to Big Sky Oil, Inc. and another investor, resulting in a change of control.

On July 28, 2014, Big Sky Oil, Inc., the majority shareholder of Med-Cannabis Pharma Inc. (the “Company”), returned to the Company’s treasury 159,930,000 shares of the Company’s common stock it had purchased from prior management. Big Sky agreed to return these shares to the treasury for use in future possible issuances by the Company.

NOTE 8 – Related Party Transactions

The Company operates under an agreement with Bendor Investments, LTD, a related party, under which MCPI receives a fee for managing Bendor’s retail stores.

South Beach Live, Inc. a related party directly transferred 1,000,000 shares of its MCPI stock to consultants in return for services to the Company. South Beach does not expect repayment and this transaction was treated as donated capital.

As September 30, 2015 the Company had a line-of-credit (”LOC”) to a related party stockholder in the amount of $873,597, with interest at 10% annually. This LOC was entered into on July 28, 2014 and replaced the shareholder note that was assumed during the change of control transaction. During the nine months ended September 30, 2015 Interest expense on the LOC was $50,661.

$41,628 of the Company’s accounts payable and accrued expenses are to related parties. $24,923 of this amount was assumed when current management took control.

In the change of control agreements dated March 27, 2014, $1,806 of related party debt was forgiven by a former shareholder.

13

NOTE 9 – Recent Accounting Pronouncements Auditors please update

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201416—Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update do not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. That is, an entity will continue to evaluate whether the economic characteristics and risks of the embedded derivative feature are clearly and closely related to those of the host contract, among other relevant criteria. The amendments clarify how current GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. The effects of initially adopting the amendments in this Update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201417—Business Combinations (Topic 805): Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The amendments in this Update are effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. However, if the financial statements for the period in which the most recent change-in-control event occurred already have been issued or made available to be issued, the application of this guidance would be a change in accounting principle.

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements – Going Concerns (Subtopic 205-40): Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “DevelopmentDevelopment Stage Entities”.Entities.  The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP.  In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information inon the statements of income, cash flows, and shareholdershareholder’s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.  The amendments in this update are applied retrospectively. The adoption of ASU 2014-10 removed the development stage entity financial reporting requirements from the Company.

14

In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The new guidance requires that share-based compensation that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards and that could be achieved after an employee completes the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation costs should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this Update either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on our financial position or results of operations. In June 2014, the FASB issued ASU No. 2014-10: Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation , to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements of development stage entities. The amendments in this update remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, thereby improving financial reporting by eliminating the cost and complexity associated with providing that information. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public companies, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Earlytherein, and early adoption is permitted.  The adoption ofCompany evaluated and adopted ASU 2014-10 commencing with the reporting period ended June 30, 2014.


The Company is of the opinion that any and all other pending accounting pronouncements, either in the adoption phase or not expectedyet required to be adopted, will not have a materialsignificant impact on ourthe Company's financial position or results of operations.

Besides what’s noted above


Note F - Fair Value of Financial Instruments

The carrying amount of cash, accounts receivable, accounts payable and notes payable, as applicable, approximates fair value due to the short term nature of these items and/or the current interest rates payable in relation to current market conditions.

11


MCPI, Inc.
Notes to Financial Statements
September 30, 2015 and December 31, 2014
(Unaudited)


Note F - Fair Value of Financial Instruments - Continued

Interest rate risk is the risk that the Company’s earnings are subject to fluctuations in interest rates on either investments or on debt and is fully dependent upon the volatility of these rates.  The Company does not use derivative instruments to moderate its exposure to interest rate risk, if any.

Financial risk is the risk that the Company’s earnings are subject to fluctuations in interest rates or foreign exchange rates and are fully dependent upon the volatility of these rates.  The Company does not use derivative instruments to moderate its exposure to financial risk, if any.

Note G - Property and Equipment

Property and equipment consist of the following components:

  September 30,  December 31, Estimated
  2015  2014 useful life
        
Furniture, fixtures and equipment $30,845  $ 3-5 years
Leasehold improvements  27,509    10 years
   58,354     
Accumulated depreciation  (6,974)    
          
Net property and equipment $51,380  $  

Total depreciation expense charged to operations for the nine months ended September 30, 2015 and 2014 was approximately $6,974 and $-0-, respectively.

Note H - Notes Payable to Stockholders

On July 28, 2014, the Company entered into a $500,000 Line of Credit note payable with South Beach Live, Ltd. (South Beach), a Company stockholder and an entity related to a significant Company stockholder, to provide funds necessary to support the corporate entity and provide working capital to pursue business combination or acquisition opportunities.  This note bore interest at 10.0% and matured in July 2015.  This note replaced a non-interest bearing shareholder note payable to a former controlling stockholder that was assumed during a 2014 change in control transaction.  During the twelve months ended December 31, 2014, the Company recognized an aggregate $4,973 as additional paid-in capital for the economic event related to the non-interest bearing feature on the assumed note payable through its retirement.

On September 30, 2015, the Company executed a replacement Promissory Note with the principal stockholder of South Beach Live, Ltd. in the amount of $927,000, bearing interest at 12.0% and payable in monthly installments of approximately $13,300, including accrued interest with a final maturity and balloon payment due on October 31, 2016.

As of September 30, 2015, the outstanding balance on this note is approximately $538,504, inclusive of the effect of the June 1, 2016 Settlement Agreement, as the lender continues to advance funds to support the Company’s working capital needs.  The Company is delinquent in making the required monthly installment payments.




(Remainder of this page left blank intentionally)

12


MCPI, Inc.
Notes to Financial Statements
September 30, 2015 and December 31, 2014
(Unaudited)


 Note I - Income Taxes

The components of income tax (benefit) expense for the each of the nine month periods ended September 30, 2015 and 2014, respectively, are as follows:

  Nine months  Nine months 
  ended  ended 
  September 30,  September 30, 
  2015  2014 
Federal:      
Current $  $ 
Deferred      
       
State:        
Current      
Deferred      
       
         
    Total
 $  $ 

As of September 30, 2015, the Company had aggregate net operating loss carryforward(s) to offset future taxable income of approximately $1,200,000.   The amount and availability of any net operating loss carryforward(s) will be subject to the limitations set forth in the Internal Revenue Code.  Such factors as the number of shares ultimately issued within a three year look-back period; whether there is a deemed more than 50 percent change in control; the applicable long-term tax exempt bond rate; continuity of historical business; and subsequent income of the Company all enter into the annual computation of allowable annual utilization of any net operating loss carryforward(s).

The Company's income tax (benefit) expense for the each of the nine month periods ended September 30, 2015 and 2014, respectively, are as follows:

  Nine months  Nine months 
  ended  ended 
  September 30,  September 30, 
  2015  2014 
       
Statutory rate applied to income before income taxes $(189,400) $(270,500)
Increase (decrease) in income taxes resulting from:        
State income taxes      
Other, including reserve for deferred tax asset        
and application of net operating loss carryforward(s)  189,400   270,500 
         
    Income tax expense
 $  $ 


Note J - Common Stock Transactions

On March 23, 2016, the Company filed an amendment to its Articles of Incorporation stating “After giving effect to a ten for one reverse split, Article III is amended to read as follows: The total number of shares of all classes of stock which the Corporation shall have the authority to issue is five hundred twenty five million (525,000,000) shares, of which five hundred million (500,000,000) shares, par value $0.001 per share, shall be designated as “Common Stock” and twenty five million (25,000,000) shares, par value $0.001 per share, shall be designated as “Preferred Stock.”  The effect of this action is reflected in the accompanying financial statements as of the first day of the first period presented.

On March 27, 2014, the then-controlling shareholders of the Company sold 210,000,000 issued and outstanding shares of the Company to Big Sky Oil, Inc. and another investor in a private transaction, effecting a change in control of the Company.

On July 28, 2014, Big Sky Oil, Inc., the majority shareholder of the Company, as a result of the March 2014 change in control transaction, surrendered for no compensation and returned to the Company’s treasury 159,930,000 shares of the Company’s common stock it had acquired in the March 2014 transaction.  Big Sky agreed to return these shares to the treasury for use in future possible issuances by the Company.

13


MCPI, Inc.
Notes to Financial Statements
September 30, 2015 and December 31, 2014
(Unaudited)


Note J - Common Stock Transactions - Continued

During the period ending December 31, 2014, the Company issued an aggregate of 100,000 shares for consulting services rendered in conjunction with due diligence related to providing back-office and other support services to marijuana dispensaries located in both Oregon and Washington State.  These shares were valued at $30,000 using the closing price on the date the shares were issued.

On January 15, 2015, the Company issued an aggregate of 50,000 shares for consulting services related to the provision of back-office and other management support services to marijuana dispensaries located in the State of Oregon.  This stock was valued at $0.30 per share, which approximated the closing price on date of the issuance.

During the period ended March 31, 2015, South Beach Live, Inc., a corporation controlled by a majority shareholder of the Company, transferred 1,000,000 shares of its holdings in the Company’s common stock to consultants for ongoing services associated with marketing strategies.  South Beach Live, Inc. is a related party and does not expect to be repaid for this transaction which was valued at approximately $300,000 and recorded as professional fees and contributed capital on the books of the Company.

Note K - Preferred Stock

The Company is authorized to issue up to 25,000,000 shares of preferred stock, $0.001 par value.  As of September 30, 2015, there are no shares of preferred stock issued and outstanding.

Note L - Subsequent Events

The Company’s operating subsidiary, High Desert MMJ, Inc., learned in early-October 2015 that the 1.0% minority partner in the Emerald Mountain Organics joint venture had absconded with all of the assets of the joint venture.  Efforts to locate and recover said assets were unsuccessful.  Accordingly, effective October 10, 2015, High Desert MMJ, Inc. abandoned the Emerald Mountain Organics joint venture and wrote off said investment.  The cumulative start-up losses in the Company’s consolidated financial statements for the Emerald Mountain Organics joint venture, through September 30, 2015, were approximately $50,000.

On February 29, 2016, the Company filed a Definitive Information Statement on Schedule 14C with the Securities and Exchange Commission noting a pending 1 for 10 reverse split of the Company’s issued and outstanding common stock; as approved by the Company’s Board of Directors, and a concurrent amendment to the Company’s Articles of Incorporation setting the authorized capital of the Company from the authorized, as adjusted, 25,000,000 post-split shares of common stock to 500,000,000 shares of $0.001 par value common stock and the authorized, as adjusted, 250,000 post-split shares of preferred stock to 25,000,000 shares of $0001 par value preferred stock.  This action is anticipated to be completed during the 2nd quarter of Calendar 2016.

On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.  The Settlement Agreement relates to the Company’s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.  The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.

The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company’s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.  Bendor disputed this claim.  To resolve the dispute, the parties agreed to forgive the accrued management fees and offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.  Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.

Management has evaluated all other activity of the Company through the issue date of the financial statements and concluded that no subsequent events have occurred that would require recognition in the accompanying financial statements or disclosure in the notes to financial statements.

14


Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

(1) Caution Regarding Forward-Looking Information

Certain statements contained in this annual filing, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business  disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.

Given these uncertainties, readers of this Form 10-Q and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

(2) General

The Company was originally incorporated as Southwest China Imports, Inc. on February 23, 2011 in the State of Nevada.  The Company’s initial business plan was to import high-end handmade lace wigs, hairpieces, and other beauty supplies and accessories manufactured overseas into the United States.

In June 2014, the Company changed its name to Med-Cannabis Pharma, Inc. and implemented a new business plan to enter into the retail sale of medical and personal use  marijuana, where allowable.  In October 2015, the Company changed its name to MCPI, Inc.

Effective March 31, 2016, the Company ceased activities in all of its subsidiaries and disposed of Med-Pharma Management, Inc. and High Desert MMJ, Inc.  Prior thereto, the Company’s  subsidiaries were Medical Management Systems, Inc., an Oregon corporation engaged in providing back-office and support services to marijuana dispensaries in the State of Oregon; Med-Pharma Management, Inc., a Washington State corporation which was formed to own, manage or provide back-office and support services to marijuana dispensaries in Washington State; and High Desert MMJ, Inc. an Oregon corporation, which is a 99.0% partner in Emerald Mountain Organics, an Oregon joint venture, formed to facilitate the development and growing of medical marijuana plants for wholesale distribution to licenced dispensaries in the State of Oregon.

As of September 30, 2015, Medical Management Systems, Inc. held a Management Contract for three marijuana dispensaries located in Newport, Bend and Cottage Grove, Oregon; which are owned by a company controlled by a related party.  This Management Contract was terminated by the consent of both parties, effective March 31, 2016.   Med-Pharma only conducted introductory due diligence efforts in the State of Washington and, currently, has abandoned all activities in the State of Washington.  Emerald Mountain Organics had, as of September 30,2015, established an early-phase growing operation and has generated nominal sales.

During the first 10 days of October 2015, the Company’s subsidiary, High Desert MMJ, Inc., learned that the 1.0% minority partner in the Emerald Mountain Organics joint venture had absconded with all of the assets of the joint venture.  Efforts to locate and recover either the individuals representing said 1.0% minority partner or the said absconded assets were unsuccessful.  Accordingly, effective October 10, 2015, High Desert MMJ, Inc. abandoned the Emerald Mountain Organics joint venture and wrote off said investment.  The cumulative start-up losses in the Company’s consolidated financial statements for the Emerald Mountain Organics joint venture, through the date of abandonment were approximately $53,000 and the Company recognized a loss on the stolen assets of approximately $51,000 during the quarter ended December 31, 2015.

On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.  The Settlement Agreement relates to the Company’s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.  The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.

The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company’s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.  Bendor disputed this claim.  To resolve the dispute, the parties agreed to forgive the accrued management fees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.  Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.  The effect of the June 1, 2016 Settlement Agreement , due to the timing of this release of these amended financial statements and this transaction, is reflected in the accompanying consolidated financial statements.
15


(3) Results of Operations

The Company has recognized revenues of approximately $20,600 during the quarter ended September 30, 2015, solely from the efforts of the Company’s interest in the Emerald Mountain Organics joint venture with affiliated direct costs of sales of approximately $25,500.  As previously discussed, this operation was written off in October 2015 due to the theft of all assets and disappearance of the minority joint venture partners.

The Company incurred general operating expenses of approximately $529,000 and $113,000 during each of the respective nine month periods ended September 30, 2015 and 2014.  These expenses were predominately related to legal and professional fees, efforts to implement the Company’s business plan and start-up costs affiliated with the Emerald Mountain Organics joint venture.  Expenditure levels are anticipated to fluctuate depending on the Company’s activities related to its stated business plan.

Loss per share for each of the nine-month periods ended September 30, 2015 and 2014 were $(0.01) and $(0.01), respectively, based on the weighted-average shares issued and outstanding during each period.

The Company does not expect to generate any meaningful revenue or incur operating expenses for purposes other than fulfilling the impactobjectives of recent accounting pronouncementsthe Company’s business plan, as previously stated, and the obligations of being a reporting company under the Securities Exchange Act of 1934.

(4) Plan of Business

The Company’s operating subsidiary, High Desert MMJ, Inc., learned in early-October 2015 that the 1.0% minority partner in the Emerald Mountain Organics joint venture had absconded with all of the assets of the joint venture.  Efforts to locate and recover said assets were unsuccessful.  Accordingly, effective October 10, 2015, High Desert MMJ, Inc. abandoned the Emerald Mountain Organics joint venture and wrote off said investment.  The cumulative start-up losses in the Company’s consolidated financial statements for the Emerald Mountain Organics joint venture, through September 30, 2015, were approximately $50,000.

On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.  The Settlement Agreement relates to the Company’s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.  The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.

The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company’s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.  Bendor disputed this claim.  To resolve the dispute, the parties agreed to forgive the accrued management fees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.  Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.

The Company is seeking other business opportunities at this time; however, as of the release date of this report, the Company has no definitive agreement or other arrangement related to any potential business transaction.

(5) Liquidity and Capital Resources

At September 30, 2015 and December 31, 2014, respectively, the Company had working capital of approximately $(34,000) and $(18,000), respectively; exclusive of all related party accounts, accrued expenses and line-of-credit notes payable.

It is the belief of management and significant stockholders that they will provide sufficient working capital necessary to support and preserve the integrity of the corporate entity.   However, there is no legal obligation for either management or significant stockholders to provide additional future funding.  Further, the Company is at the mercy of future economic trends and business operations for the Company’s majority stockholder to have the resources available to support the Company.  Should this pledge fail to provide financing, the Company has not identified any alternative sources.  Consequently, there is substantial doubt about the Company's ability to continue as a materialgoing concern.

The Company's need for working capital may change dramatically as a result of any future business transaction.  There can be no assurance that the Company will identify and/or enter into any business transaction in the future.  Further, there can be no assurance that the Company would be successful in consummating any acquisition on favorable terms or that it will be able to profitably manage the business, product, technology or company it acquires.

The Company has no current plans, proposals, arrangements or understandings with respect to the sale or issuance of additional securities prior to the location of a potential business transaction.  Accordingly, there can be no assurance that sufficient funds will be available to the Company to allow it to cover the expenses related to such activities.
16


Regardless of whether the Company’s cash assets prove to be inadequate to meet the Company’s operational needs, the Company might seek to compensate providers of services by issuances of stock in lieu of cash.

(6) Critical Accounting Policies

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“GAAP”).  GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue and expense amounts reported.  These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition.  We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied.  We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances.  Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Our significant accounting policies are summarized in Note D of our financial statements.  While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates.  Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our consolidated results of operations, financial position or liquidity for the periods presented in this report.

Item 3 - Quantitative and Qualitative Disclosures About Market Risk

Not required of a smaller reporting company.

Item 4 - Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive and Financial Officer (Certifying Officer), have evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15 promulgated under the Exchange Act as of the end of the period covered by this Amended Quarterly Report.  Disclosure controls and procedures are controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms and include controls and procedures designed to ensure that information we are required to disclose in such reports is accumulated and communicated to management, including our Certifying Officer, as appropriate, to allow timely decisions regarding required disclosure.  Based upon that evaluation, our Certifying Officer have concluded that as of such date, our disclosure controls and procedures were not effective to ensure that the information required to be disclosed by us in our reports is recorded, processed, summarized and reported within the time periods specified by the SEC due to a inherent weakness in our internal controls over financial reporting due to our status as a shell corporation and having a sole supervising officer.  However, our Certifying Officer believes that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the respective periods presented.

(b) Changes in Internal Controls and Corrective Actions

During the third and fourth quarter of 2015, former management, independently, undertook procedures, protocols and decisions to circumvent the reporting nature and requirements of the Management Agreement that Medical Management Systems, Inc, a wholly-owned subsidiary of the Company, had with medical marijuana dispensaries owned by an entity controlled by personnel in common with the Company’s controlling shareholder.  It is believed that these individuals also conspired with the minority joint venture partners in Emerald Mountain Organics to facilitate the theft of all operating assets and operations of the joint venture.  Current management, with the assistance of outside consultants and input from the Company’s controlling shareholder and owner of the medical marijuana dispensaries covered by the Medical Management Systems Management Contract, identified the errors and mistatements applied by former management and has made the appropriate corrections in the accompanying financial statements.

NOTE 10 – Subsequent Events

October 1, 2015-Recreation marijauna sales became legal in Orgeon. As allowed by law  Additionally, the Company commenced recreational sales through its medical despensaries.

has initiated litigation against the Company’s former President and Chief Executive Officer and others to recover either the absconded assets or their value, the value of the products in the then-current growing cycle and other damages incurred by the Company as a result of the alleged misappropriations.  It is the opinion of current management and the Company’s controlling shareholder that all appropriate corrective actions have been taken and applied.
15

There were no other significant changes (including other corrective actions with regard to significant deficiencies or material weaknesses) in our internal controls over financial reporting that occurred during the quarter ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 

October

17

Part II - Other Information

Item 1 - Legal Proceedings

None

Item 1A – Risk Factors

We are a smaller reporting company as defined by Reg. 240.12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3 - Defaults Upon Senior Securities

None

Item 4 - Mine Safety Disclosure

N/A

Item 5 - Other Information

On August 7, 2015, – EntryMed-Cannabis Pharma, Inc. (the “Company”) entered into a Material Definitive Agreement: MCPI,non-binding letter of intent to purchase World of Weed, Inc., a Colorado corporation, which operates medical marijuana grow facilities and operates medical and recreational marijuana sales facilities in Colorado.  No definitive agreement were executed by the parties at that time and the closing of the transaction was subject to due diligence review and other terms and conditions to be negotiated by and between the parties.

On September 30, 2015, Med-Cannabis Pharma, Inc. (the “Company”) entered into a Purchase Agreement (the “Agreement”) with World of Weed, Inc. (“WOW”), a Colorado corporation. Pursuant to the Agreement, and upon the terms and subject to the conditions thereof, at the closing, the Company will issue 10.02 shares of its common stock in exchange for each share of WOW stock currently issued and outstanding.  If all the WOW shares are exchanged, the Company would issue a total of 50,100,000 shares of its common stock to WOW shareholders. If all these shares are issued, the WOW shareholders will own approximately 50.00149% of the Company. WOW owns and operates a retail marijuana store and a grow operation in Colorado Springs, Colorado.

As part of the proposed acquisition of WOW, the Company has appointed Anthony C. Russo as a director to replace Mr. Burch. The Company has increased the size of its Board from three to five and added two additional directors: Tony Pugliese and Leonard Armenta.

October 22, 2015 – Termination of a Material Definitive Agreement: Previously, on September 30, 2015, MCPI, Inc. (the “Company”) announced that it had entered into a Purchase Agreement (the “Agreement”) with World of Weed, Inc. (“WOW”), a Colorado corporation. Subsequently  Subsequent to entering into this Agreement but prior to the closing of the Agreement, WOW’s counsel informed the parties to the Agreement that the proposed transaction would not be in compliance with Colorado law and that the proposed transaction could not be consummated.

As part of the anticipated transaction, the Company had appointed three new directors: Anthony Russo, Tony Pugliese and Leonard Armenta. The majority shareholder of the Company, acting by majority written consent


Item 6 - Exhibits

31.1          Certification pursuant to the Company’s Bylaws, votedSection 302 of Sarbanes-Oxley Act of 2002 - Chief Executive/Financial Officer
32.1          Certification pursuant to remove these three new directors.

October 30, 2015 Graciela Moreno resigned as Director, President, andSection 906 of Sarbanes-Oxley Act of 2002 - Chief executive off ice or the Company. On that day the Board appointed Garrett Vogel, the Company’s CFOExecutive/Financial Officer

101           Interactive data files pursuant to assume the roleRule 405 of interim CEO

16
Regulation S-T.  (+)

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

We are a corporation with limited operations. Our independent registered public accounting firm has issued a going concern opinion in their audit report dated December 31, 2014, which can

(+) - to be found in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on May 14, 2015. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next 12 months. Accordingly, we must raise additional cash to sustain our limited operations.

We presently are exploring other such sources of funding, including raising funds through a second public offering, a private placement of securities, or loans. If we are unable to raise this additional funding, we will either have to suspend operations until we do raise the cash or cease operations entirely.

The following discussion should be read in conjunction with our Financial Statements and the notes thereto and the other information included in this Quarterly Report as filed with the SEC on Form 10-Q.

Limited Operating History; Need for Additional Capital

There is limited historical financial information about us upon which to base an evaluation of our performance. We remain in the start-up stage of operations and have only begun to generate nominal revenue. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns, such as increases in marketing costs, increases in administration expenditures associated with daily operations, increases in accounting and audit fees, and increases in legal fees related to filings and regulatory compliance.

Currently, we do not have any arrangements for additional financing. We have no assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop, or expand our operations. Equity financing could result in additional dilution to existing shareholders.

Plan of Operations

The medical marijuana dispensaries, which are currently in operations legally within the states that medical marijuana has been approved and is legal. Currently the Company has operating and is negotiating with existing dispensaries in Oregon.

The company intends to further expandseparately by acquiring or opening medical marijuana dispensaries in locations where an acquisition is not readily available such as states where medical marijuana has been newly legalized. The new locations will be based on medicinal demand and location analysis to support maximum potential of success.

The Company currently has corporate offices in Newport Oregon.

17
amendment

Results of Operations

Three months Ended September 30, 2015 and 2014

Revenues. We generated revenues of $59,555 during the three months ended September 30, 2015compared to $0 for the same period a year ago

Gross Profit. Our gross loss was $17,864 and $0 during the three months ended September 30, 2015 and for the same period a year ago, respectively.

Operating Expenses. Our total operating expenses for the three months ended September 30, 2015 were $180,510, which is a $132,075 or 273%,increase compared to operating expenses of $48,435 for the same period a year ago. The increase in expenses was primarily attributable to increased general and administrative cost from arising from more personnel, paying previously unpaid personnel, and increased accounting costs.

Income (Loss) From Operations. We had a loss from operations of $198,374 for the three months ended September 30, 2015 compared to an operating loss of $48,435 for the same period a year ago, which represented a $149,939 increase in operating loss.

Other income (expenses). During the three months ended September 30, 2015 we recorded $27,509 interest, compared to $3,753 the same period a year ago. The interest expense is comprised of interest payable related to line-of-credit interest and notes outstanding payable to a related party. In increase is due to higher balances outstanding.

Net Income (Loss). We had a net loss of $225,883 for the three months ended September 30, 2015 compared to a net loss of $52,188 for the same period a year ago, which represented an increase of $173,695, in net loss.  

Total Stockholders’ Deficit. Our stockholders’ deficit was $827,060 as of September 30, 2015.

Nine months Ended September 30, 2015 and 2014

Revenues. We generated revenues of $69,555 during the nine months ended September 30, 2015compared to $0 for the same period a year ago.. Increases are particaly due to an additional store coming on-line

Gross Profit. Our gross loss was $17,095 and $0 during the Nine months ended September 30, 2015 and for the same period a year ago, respectively.

Operating Expenses. Our total operating expenses for the nine months ended September 30, 2015 were $727,870, which is a $614,995 or 548%,increase compared to operating expenses of $112,875 for the same period a year ago. The increase in expenses was primarily attributable to increased general and administrative cost from arising from more personnel, paying previously unpaid personnel, and increased accounting costs.

Income (Loss) From Operations. We had a loss from operations of $744,965 for the nine months ended September 30, 2015 compared to an operating loss of $112,875 for the same period a year ago, which represented a $632,090 increase in operating loss.

18

Other income (expenses). During the nine months ended September 30, 2015 we recorded $50,661 interest, compared to $7,862 the same period a year ago. The interest expense is comprised of interest payable related to line-of-credit interest and notes outstanding payable to a related party. In increase is due to higher balances outstanding.

Net Income (Loss). We had a net loss of $795,965 for the nine months ended September 30, 2015 compared to a net loss of $112,875 for the same period a year ago, which represented an increase of $674,889, in net loss.  

Liquidity and Capital Resources

As September 30, 2015, we had $178,544 of assets. Our total liabilities were $1,005,604, which consisted of accounts payable of $44,490, accrued expenses of $87,516 and a line-of-credit aggregating $873,597 to a related party. The LOC has a 10% annual interest rate. Further, we had no external credit facilities (i.e. bank loans, revolving lines of credit, etc.).

Based on the initial increase in volume due to the legalization of recreational marijuana sales we expect to achieve profitability and positive cash flow in early 2016. We believe that we need at least $4,000,000 in additional funds to achieve our short-term physical expansion and marketing/brand development plans while meeting our responsible l working capital requirements over the next 12 months.

We are presently exploring various sources of funding, including raising funds through a secondary public offering, a private placement of our securities, or loans. Without limiting our available options, future equity financings will most likely be through the sale of additional shares of our common stock. It is possible that we could also offer warrants, options and/or rights in conjunction with any future issuances of our common stock. However, we can give no assurance that financing will be made available to us, and if made available to us, in amounts or on terms acceptable to us. If we cannot secure adequate financing, we may be forced to cease operations and you will lose your entire investment.

Going Concern Consideration

Our independent registered public accounting firm has issued a going concern opinion in their audit report dated May 13 , 2015, which can be found in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on May 14, 2015. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next 12 months. Our financial statements found within this Quarterly Report on Form 10-Q and the aforementioned Annual Report on Form 10-K contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

Off –Balance Sheet Operations

As of September 30, 2015, we had no off-balance sheet activities or operations.

19
SIGNATURES

CRITICAL ACCOUNTING POLICIES

The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”) for financial information and in

In accordance with the Securities and Exchange Commission’s (“SEC”) Regulation S-X. They reflect all adjustments which are, in the opinion of Med-Cannabis Pharma’s management, necessary for a fair presentationrequirements of the financial position and operating results as of and forExchange Act, the three months ended September 30, 2015 and 2014.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported revenues and expenses during the reporting periods. Because of the use of estimates inherent in the financial reporting process, actual results may differ significantly from those estimates.

Cash and Cash Equivalents

For purposes of the statement of cash flows, Med-Cannabis Pharma considers highly liquid financial instruments purchased with a maturity of three months or lessregistrant caused this report to be cash equivalents. As of September 30, 2015, we had $10,360 in cash and equivalents.

Fair Value of Financial Instruments

ASC 820, “Fair Value Measurements” and ASC 825, Financial Instruments, requires an entity to maximizesigned on its behalf by the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

undersigned, thereunto duly authorized.
LevelDescription
  
Level 1Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

[This space intentionally left blank.]

20

The estimated fair values of the Company’s financial instruments are as follows:

 

 

Fair Value Measurement at September 30, 2015 Using:

         

 

 

 

 

 

Description

 

 

 

 

 

 

9/30/15

 

Quoted

Prices In

Active

Markets For

Identical

Assets 

(Level 1)

 

 

Significant

Other

Observable

Inputs

(Level 2)

 

 

 

Significant

Unobservable

Inputs 

(Level 3)

Assets        
 Cash and equivalents$31,082$31,082$-$-
 $31,082$31,082$-$-
         
Liabilities        
 Accounts payable$44,490$44,090$-$-
 Accrued Expenses 87,516 87,516    
    Note payable to stockholder 873,597 873,597 - -
 $1,005,604$1,005,604$-$-

 

 

Fair Value Measurement at December 31, 2014 Using:

         

 

 

 

 

 

Description

 

 

 

 

 

 

12/31/14

 

Quoted

Prices In

Active

Markets For

Identical

Assets 

(Level 1)

 

 

Significant

Other

Observable

Inputs

(Level 2)

 

 

 

Significant

Unobservable

Inputs 

(Level 3)

Assets        
 Cash and equivalents$14,463$14,463$-$-
 $14,463$14,476$-$-
         
Liabilities        
 Accounts payable$6,285$6,285$-$-
 Accrued Expenses 26,333 26,333    
 Deferred 5,000 5,000 - -
    Note payable to stockholder 323,579 323,579 - -
 $361,197$361,197$-$-

Net Loss per Share Calculation

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per shares is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. During the three months ended September 30, 2015 we had no dilutive financial instruments issued or outstanding.

21

Revenue Recognition

Med-Cannabis Pharma follows the guidance of FASB ASC Topic 605 for revenue recognition. In general, Med-Cannabis Pharma recognizes revenue when (1) the price is fixed and determinable, (2) persuasive evidence of an arrangement exists, (3) the service has been provided, and (4) collectability is reasonably assured.

Med-Cannabis Pharma generates revenue from managing the operations of Medical Marijuana dispensaries owned by others.

Income Taxes

We account for income taxes pursuant to FASB ASC 740, Income Taxes. Under FASB ASC 740-10-25, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

We maintain a valuation allowance with respect to deferred tax assets. Med-Cannabis Pharma establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration Med-Cannabis Pharma’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

Changes in circumstances, such as Med-Cannabis Pharma generating taxable income, could cause a change in judgment about its ability to realize the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

Recently Issued Accounting Pronouncements Auditors Please Review

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201416—Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update do not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. That is, an entity will continue to evaluate whether the economic characteristics and risks of the embedded derivative feature are clearly and closely related to those of the host contract, among other relevant criteria. The amendments clarify how current GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. The effects of initially adopting the amendments in this Update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201417—Business Combinations (Topic 805): Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The amendments in this Update are effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. However, if the financial statements for the period in which the most recent change-in-control event occurred already have been issued or made available to be issued, the application of this guidance would be a change in accounting principle.

22

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements – Going Concerns (Subtopic 205-40): Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “Development Stage Entities”. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in this update are applied retrospectively. The adoption of ASU 2014-10 removed the development stage entity financial reporting requirements from the Company.

In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The new guidance requires that share-based compensation that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards and that could be achieved after an employee completes the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation costs should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this Update either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on our financial position or results of operations. In June 2014, the FASB issued ASU No. 2014-10: Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation , to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements of development stage entities. The amendments in this update remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, thereby improving financial reporting by eliminating the cost and complexity associated with providing that information. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public companies, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The adoption of ASU 2014-10 is not expected to have a material impact on our financial position or results of operations.

Besides what’s noted above the Company does not expect the impact of recent accounting pronouncements to have a material effect on the Company’s financial statements.

23

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable since we are a smaller reporting company.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation under the supervision and with the participation of our sole officer and director, Gracie Moreno, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act).

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be presented or detected on a timely basis.

Based on management’s assessment, we have concluded that, as September 30, 2015, our disclosure controls and procedures were not effective in timely alerting management to the material information relating to us required to be included in our annual and interim filings with the SEC.

Management has concluded that our disclosure controls and procedures had the following material weaknesses:

  • We were unable to maintain any segregation of duties within our financial operations due to our reliance on limited personnel in the finance function. While this control deficiency has not resulted in any audit adjustments to our interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties;
  • Med-Cannabis Pharma lacks sufficient resources to perform the internal audit function and does not have an Audit Committee;
  • We do not have an independent Board of Directors, nor do we have a board member designated as an independent financial expert to Med-Cannabis Pharma. The Board of Directors is comprised of three (3) members, two of whom also serves as Med-Cannabis Pharma’s sole executive officer and a vice president/store manager.. As a result, there is a lack of independent oversight of the management team, lack of independent review of our operating and financial results, and lack of independent review of disclosures made by Med-Cannabis Pharma; and
  • Documentation of all proper accounting procedures is not yet complete.

These weaknesses have existed since our inception and, as of September 30, 2015, have not been remedied.

24

To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned material weaknesses, including, but not limited to, the following:

  • Considering the engagement of consultants to assist in ensuring that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures;
  • Hiring additional qualified financial personnel, including a Chief Financial Officer, on a full-time basis;
  • Expanding our current board of directors to include additional independent individuals willing to perform directorial functions; and
  • Increasing our workforce in preparation for exiting the development stage and commencing revenue producing operations.

Since the recited remedial actions will require that we hire or engage additional personnel, these material weaknesses may not be overcome in the near-term due to our limited financial resources. Until such remedial actions can be realized, we will continue to rely on the limited advice of outside professionals and consultants.

Changes in Controls and Procedures

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

25

PART II

Item 1. Legal Proceedings

No officer, director, or persons nominated for these positions, and no promoter or significant employee (current or former) of our corporation has been involved in legal proceedings that would be material to an evaluation of our management. We are not aware of any pending or threatened legal proceedings involving MCPI, Inc.

During the past ten (10) years, Gracie Moreno has not been the subject of the following events:

1)Any bankruptcy petition filed by or against any business of which Ms. Moreno was a general partner or executive officer either at the time of the bankruptcy or within two (2) years prior to that time;

2)Any conviction in a criminal proceeding or being subject to a pending criminal proceeding;

3)An order, judgment, or decree, not subsequently reversed, suspended or vacated, or any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting Ms. Moreno’s involvement in any type of business, securities or banking activities; and

4)Found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Future Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Item 1A. Risk Factors

Not applicable since we are a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Default Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

26

Item 6. Exhibits

Exhibit Number

Description of Exhibit

3.1(1)Articles of Incorporation
3.2(1)Bylaws
3.3(2)Amendment to Articles of Incorporation
31.1Section 302 Certifications under Sarbanes-Oxley Act of 2002
32.1Section 906 Certification under Sarbanes Oxley Act of 2002

(1)Incorporated by our Registration Statement on Form S-1 filed May 3, 2011.

(2)Incorporated by our Current Report on Form 8-K filed July 1, 2014.
   
   

Following are the 8-K’s filed by the Company during the quarter ended September 30, 2015 and subsequent to:

October 2, 2015 – Entry into a Material Definitive Agreement: MCPI, Inc. (the “Company”) entered into a Purchase Agreement (the “Agreement”) with World of Weed, Inc. (“WOW”), a Colorado corporation. Pursuant to the Agreement, and upon the terms and subject to the conditions thereof, at the closing, the Company will issue 10.02 shares of its common stock in exchange for each share of WOW stock currently issued and outstanding. If all the WOW shares are exchanged, the Company would issue a total of 50,100,000 shares of its common stock to WOW shareholders. If all these shares are issued, the WOW shareholders will own approximately 50.00149% of the Company. WOW owns and operates a retail marijuana store and a grow operation in Colorado Springs, Colorado.

As part of the proposed acquisition of WOW, the Company has appointed Anthony C. Russo as a director to replace Mr. Burch. The Company has increased the size of its Board from three to five and added two additional directors: Tony Pugliese and Leonard Armenta.

October 22, 2015 – Termination of a Material Definitive Agreement: Previously, on September 30, 2015, MCPI, Inc. (the “Company”) announced that it had entered into a Purchase Agreement (the “Agreement”) with World of Weed, Inc. (“WOW”), a Colorado corporation. Subsequently to entering into this Agreement but prior to the closing of the Agreement, WOW’s counsel informed the parties to the Agreement that the proposed transaction would not be in compliance with Colorado law and that the proposed transaction could not be consummated.

As part of the anticipated transaction, the Company had appointed three new directors: Anthony Russo, Tony Pugliese and Leonard Armenta. The majority shareholder of the Company, acting by majority written consent pursuant to the Company’s Bylaws, voted to remove these three new directors.

 27 

SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf by the undersigned, thereto duly authorized on this 16th day of November, 2015.

Dated: August 1, 2016 MCPI, Inc./s/ R.Wayne Duke
  
By:     /s/ Garrett Vogel
                 Garrett Vogel
                 President, Chief Executive Officer,
Chief Financial Officer,  Secretary,, and TreasurerR.Wayne Duke
  

28Chief Executive and Financial Officer

18